FLT3 and acute myeloid leukemia: Interestingly, this is in line with observations from the phase III clinical trials RATIFY and QuANTUM‐R, treating FLT3‐ITD‐positive de novo AML with FLT3‐targeting inhibitors (midostaurin and quizartinib, respectively), both reporting significant survival benefit in the male subpopulation only [14, 46].